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OBJECTIVE This study was performed to characterize the risk of stroke in elderly patients with recurrent
intermittent atrial fibrillation (AF).
BACKGROUND Although intermittent AF is common, relatively little is known about the attendant risk of
stroke.
METHODS A longitudinal cohort study was performed comparing 460 participants with intermittent AF
with 1,552 with sustained AF treated with aspirin in the Stroke Prevention in Atrial
Fibrillation studies and followed for a mean of two years. Independent risk factors for
ischemic stroke were identified by multivariate analysis.
RESULTS Patients with intermittent AF were, on average, younger (66 vs. 70 years, p , 0.001), were
more often women (37% vs. 26% p , 0.001) and less often had heart failure (11% vs. 21%,
p , 0.001) than those with sustained AF. The annualized rate of ischemic stroke was similar
for those with intermittent (3.2%) and sustained AF (3.3%). In patients with intermittent AF,
independent predictors of ischemic stroke were advancing age (relative risk [RR] 5 2.1 per
decade, p , 0.001), hypertension (RR 5 3.4, p 5 0.003) and prior stroke (RR 5 4.1, p 5
0.01). Of those with intermittent AF predicted to be high risk (24%), the observed stroke rate
was 7.8% per year (95% confidence interval 4.5 to 14).
CONCLUSIONS In this large cohort of AF patients given aspirin, those with intermittent AF had stroke rates
similar to patients with sustained AF and similar stroke risk factors. Many elderly patients
with recurrent intermittent AF have substantial rates of stroke and likely benefit from
anticoagulation. High-risk patients with intermittent AF can be identified using the same
clinical criteria that apply to patients with sustained AF. (J Am Coll Cardiol 2000;35:183–7)
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In about 25% of elderly people who have atrial fibrillation
(AF), the dysrhythmia is intermittent, spontaneously arising
and remitting with highly variable frequency, duration and
symptoms (1–6). Stroke rates and risk factors are less well
characterized in patients with intermittent (paroxysmal) AF
as compared with those with sustained (constant) AF (7–9).
Patients with intermittent AF are typically younger and
have less associated cardiovascular disease versus those with
sustained AF. While it is commonly held that patients with
intermittent AF have a lower risk of stroke than those with
sustained AF (1,10,11), the pattern of AF has not emerged
as an independent predictor of stroke in multivariate anal-
yses of elderly cohorts with this dysrhythmia (12–17).
Regarding selection of antithrombotic prophylaxis, it is not
known whether risk factors used to stratify stroke risk in AF
patients apply specifically to those with intermittent AF.
We analyzed stroke rates and predictors of stroke among
460 participants with intermittent AF given aspirin in the
Stroke Prevention in Atrial Fibrillation (SPAF) I-III stud-
ies and compared them with participants with sustained AF.
METHODS
Participants in the SPAF I, II and III clinical trials (1987 to
1997) assigned to aspirin (325 mg/day) or to a combination
of aspirin plus inefficacious fixed-dose warfarin in the SPAF
III trial were considered in this analysis. The design,
participant features and main results of these trials have
been reported (18–23); these were carried out in compliance
with local regulations governing human research. In brief,
participants were adults with documented sustained or
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recurrent AF without mitral stenosis or prosthetic cardiac
valves recruited from inpatient and outpatient facilities at
two dozen clinical sites. Those under age 60 years without
associated cardiovascular disease (“lone AF”) and heavy
alcohol users precluding safe anticoagulation were not eli-
gible. Participants in the SPAF III trial assigned aspirin plus
fixed, low-dose warfarin were included if the international
normalized ratio (INR) did not exceed 1.4 during follow-up
(mean achieved INR 5 1.1, n 5 290), because INRs below
1.5 offer minimal protection against ischemic stroke in
patients with AF (18,24,25).
Atrial fibrillation was categorized as intermittent if sinus
rhythm was documented within 12 months before study
entry for SPAF I and II participants and within three
months for SPAF III subjects. Diagnosis of intermittent AF
required at least two electrocardiogram (ECG)-documented
episodes before entry, no reversible cause of AF (e.g.,
thyrotoxicosis, pneumonia) and no iatrogenic cardioversion
unless AF recurred before entry. For this analysis, those
classified as intermittent AF with AF on the entry ECG
and no subsequent documentation of sinus rhythm during
the next six months were reclassified as sustained AF (n 5
86; 16% of those initially classified as intermittent). When
ischemic stroke occurred within the first six months after
entry, the pattern of AF was classified based on observations
before the stroke. Participants undergoing therapeutic car-
dioversion during the initial six months using drugs (n 5
31) or countershock (n 5 22) were included in the main
analysis, except as otherwise specified. Hypertension was
diagnosed if blood pressure exceeded either 160 mm Hg
systolic or 90 mm Hg diastolic on repeated observations
over six months or if chronic antihypertensive medication
was required.
Patients were followed in clinic every three to six months
to assess compliance and detect strokes. Stroke events were
verified and categorized as cardioembolic, noncardioembolic
or of uncertain cause by a central events committee unaware
of treatment using a clinical classification scheme (26). A
risk stratification scheme previously derived from this cohort
by multivariate analysis was used to compare predictors of
thromboembolism in patients with intermittent versus sus-
tained AF (15).
Baseline characteristics of the intermittent versus sus-
tained AF groups were compared using the Student t test
for continuous variables and the chi-square test for categor-
ical variables. The age-adjusted relative risk (RR) for stroke
associated with a characteristic was estimated using a Cox
proportional hazards model after first including the variable
age. Differences in age-adjusted RRs between the intermit-
tent and sustained AF patients were evaluated by fitting the
model, adjusting for age, pattern of AF and factor of
interest, and then testing significance of the interaction term
for pattern of AF and factor of interest. Independent
predictors of stroke were identified by a combination of
forward and backward stepwise modeling techniques (Cox
proportional hazards model). Statistical significance in each
of these cases was assessed using the likelihood ratio
statistic. Stroke rates were expressed per patient-year of
observation, with 95% confidence intervals (CIs) deter-
mined from the Poisson distribution. Rates were compared
between groups using a Poisson regression model. Analyses
were done using SPSS and EGRET statistical software. All
tests were two sided; statistical significance was accepted at
the 95% confidence level (p , 0.05).
RESULTS
Among 2,012 SPAF participants receiving aspirin or aspirin
plus inefficacious doses of warfarin, AF was classified as
intermittent in 460 (23%). Those with intermittent AF
(mean age 66 years) were, on average, four years younger
than those with sustained AF (p , 0.001), were more often
women (p , 0.001) and had lower frequencies of heart
failure and peripheral arterial disease (Table 1). During the
initial six months of observation, 72% of SPAF III partic-
Abbreviations and Acronyms:
AF 5 atrial fibrillation
CI 5 confidence interval
INR 5 international normalized ratio
RR 5 relative risk
SPAF 5 Stroke Prevention in Atrial Fibrillation
TIA 5 transient ischemic attack
Table 1. Clinical Features of Participants Based on Pattern of
Atrial Fibrillation
Intermittent
AF
(n 5 460)
Sustained
AF
(n 5 1,552) p Value
Age (yrs), mean 6 SD 66 6 11 70 6 9 , 0.001
Women, % 37 26 , 0.001
Alcohol use ($14
drinks/week), %
6 9 0.02
Hypertension, % 49 54 n.s.
Diabetes mellitus, % 13 16 n.s.
Duration of AF ,1
year, %
37 22 , 0.001
History of heart failure,
%
11 21 , 0.001
Carotid surgery or
bruit, %
4 5 n.s.
Peripheral arterial
disease, %
4 7 0.009
Prior stroke or TIA, % 7 8 n.s.
Prior myocardial
infarct, %
7 10 n.s.
Moderate-severe LV
dysfunction, %
4 10 , 0.001
AF 5 atrial fibrillation; LV 5 left ventricular, qualitatively assessed by two-
dimensional precordial echocardiography; n.s. 5 not significant (p $ 0.05); TIA 5
transient ischemic attack.
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ipants with intermittent AF had recurrent AF based on
symptoms or rhythm tracings (comparable data not available
for SPAF I and II).
During a mean follow-up of two years, the observed rate
of ischemic stroke (n 5 27) was 3.2% per year (95% CI
2.2 to 4.6) among those with intermittent AF compared
with 3.3% per year (95% CI 2.7 to 4.0) for those with
sustained AF. The exclusion of patients in whom cardio-
version was attempted (4% of intermittent and 2% of
sustained AF patients) did not alter the observed stroke
rates.
Factors associated with ischemic stroke in patients with
intermittent AF by univariate analysis were age (p , 0.001),
hypertension (age-adjusted, p 5 0.002), prior stroke or
transient ischemic attack (TIA) (age-adjusted, p 5 0.007)
and peripheral arterial disease (age-adjusted, p 5 0.002)
(Table 2). Based on age-adjusted univariate analysis, systolic
blood pressure .160 was more strongly associated with
subsequent stroke in patients with sustained than intermit-
tent AF (p 5 0.06), while peripheral arterial disease was
more closely related to stroke in patients with intermittent
than sustained AF (p 5 0.02). Age (p , 0.001), hyperten-
sion (p 5 0.003) and prior stroke or TIA (p 5 0.01) were
the strongest predictors of ischemic stroke in patients with
intermittent AF by multivariate analysis; these factors were
also predictive among those with sustained AF (Table 3).
Applying the risk stratification scheme previously derived
from the entire cohort, those with intermittent AF were
more frequently classified as low risk than were those with
sustained AF (p 5 0.004, linear association), although
differences were small (Table 4, Fig. 1). This scheme
successfully stratified participants with intermittent AF
based on observed stroke rates (Table 4, Fig. 2; p , 0.001).
About one-fourth of those with intermittent AF had
high-risk features, and in these patients the rate of ischemic
stroke was 7.8% per year (95% CI 4.5 to 14). Considering
each category of predicted stroke risk by this scheme, there
were no significant differences in observed stroke rates
between those with intermittent and sustained AF
(Table 4).
DISCUSSION
In this large cohort of patients treated with aspirin, inter-
mittent AF was associated with stroke rates comparable
with sustained AF. Predictors of ischemic stroke were also
similar, and a single risk stratification scheme predicted
stroke for patients with either pattern of AF. Nearly
one-fourth of the cohort with intermittent AF was classified
as high-risk, and their rate of ischemic stroke was substan-
tial during treatment with aspirin.
Our results are at odds with studies reporting lower rates
of stroke in patients with intermittent rather than sustained
Table 2. Factors Associated With Ischemic Stroke in Intermittent Versus Sustained AF:
Age-adjusted Relative Risks*
Intermittent AF Sustained AF
n
Age-adjusted
RR p Value n
Age-adjusted
RR p Value
Age per decade (yrs) — 2.2 , 0.001 — 2.1 , 0.001
Women 168 1.3 n.s. 398 2.0 , 0.001
Hypertension 224 3.6 0.002 832 2.3 , 0.001
Diabetes mellitus 60 1.7 n.s. 244 1.7 0.04
Alcohol use ($14 per week) 27 † n.s. 145 0.4 0.03
Systolic blood pressure .160 torr 53 1.6 n.s. 139 4.0 , 0.001
Hormone use (n 5 1,182) 41 2.2 n.s. 57 3.3 0.007
Carotid surgery or bruit 20 2.8 n.s. 77 1.4 n.s.
Prior stroke or TIA 31 4.5 0.007 128 3.2 , 0.001
Peripheral arterial disease 18 8.5 0.002 114 1.3 n.s.
*During aspirin therapy. Left atrial diameter by M-mode echocardiography averaged 4.3 cm among participants with
intermittent AF with and without stroke.
†No strokes occurred in these 27 patients. The age-adjusted RR approaches zero, but no estimate for the upper bound of the
95% confidence interval is available for the model.
AF 5 atrial fibrillation; n.s. 5 not significant (p $ 0.05); RR 5 relative risk; TIA 5 transient ischemic attack.
Table 3. Independent Predictors of Ischemic Stroke in Patients
With Intermittent and Sustained AF
Intermittent AF
(n 5 460)
Sustained AF
(n 5 1,552)
Relative
Risk p Value
Relative
Risk p Value
Age per decade 2.1 , 0.001 1.7 , 0.001
Hypertension 3.4 0.003 1.8 0.008
Prior stroke or TIA 4.1 0.01 2.7 , 0.001
Female gender — n.s. 1.8 0.004
Systolic BP .160 torr — n.s. 2.8 , 0.001
AF 5 atrial fibrillation; BP 5 blood pressure; n.s. 5 not significant (p $ 0.05);
TIA 5 transient ischemic attack.
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AF (1,3,10) and in line with case series showing no
differences in stroke between recurrent intermittent and
sustained AF (9,17,27). Patients younger than 60 years old
with “lone” AF and those with a single documented episode
of AF were not eligible for participation. Hence, our cohort
differs importantly from those in which young patients with
“lone” or isolated episodes were prevalent (3,4,9). The mean
age of our cohort was similar to that of patients with
intermittent AF seen in clinical practice (5,7,9). Previous
studies also have identified concomitant hypertension (7,30)
and age (7,9) as predictors of stroke in intermittent AF.
Treatment with adjusted-dose warfarin appears to reduce
stroke similarly for patients with either intermittent or
sustained AF, although data are limited. Among high-risk
paticipants in the SPAF III trial categorized as intermittent
AF, those given adjusted-dose warfarin had significantly
(p 5 0.01) fewer strokes (0 strokes/91 participants) than
those given aspirin and low, inefficacious doses of warfarin
(6 strokes/80 participants) (Pearce LA for the SPAF Inves-
tigators, personal communication).
Study limitations. Participants in the SPAF clinical trials
were recruited mainly from in-patient, hospital-based pop-
ulations and may not be representative of those with
intermittent AF in the general population. Furthermore,
our findings may not apply to younger, healthier and less
symptomatic outpatients with intermittent AF. The risk of
cardioembolic stroke associated with intermittent AF is
likely to be related to the frequency and duration of
paroxysms. The frequency and duration of episodes of AF
were not accurately ascertained in this study, and stroke
could not be reliably correlated with recurrence of the
dysrhythmia or with conversion to sustained AF during
follow-up (28). All participants in our study were given
aspirin, which decreases ischemic stroke by about 20% in
patients with AF (29).
Conclusions. Elderly people with recurrent intermittent
AF in this cohort had rates of ischemic stroke comparable
with those with sustained AF and shared risk factors for
stroke. The risk of stroke varies widely among those with
intermittent AF as it does for sustained AF, and our results
suggest that stroke risk can be stratified using the same
clinical features irrespective of the pattern of AF. Additional
Figure 1. Distribution according to predicted stroke risk using the
SPAF Exploratory Analysis Criteria for patients with intermittent
(n 5 460) versus sustained (n 5 1552) atrial fibrillation.
Figure 2. Observed rates of ischemic stroke according to risk
category.
Table 4. Risk Stratification for Ischemic Stroke: SPAF III Exploratory Analysis Criteria*
Risk Stratum
Intermittent AF Sustained AF
n
Percent
of Cohort
Observed Stroke
Rate (95% CI) n
Percent
of Cohort
Observed Stroke
Rate (95% CI)
High 112 24 7.8 (4.5 to 14) 459 30 8.7 (6.8 to 11)
(Any of: age .75 and hypertension, age
.75 and female, systolic BP .160
torr, prior stroke or TIA)
Moderate 148 32 3.8 (2.2 to 6.7) 530 34 2.3 (1.6 to 3.4)
(Either of: hypertension and age #75
yr, diabetes; and no high-risk
features)
Low 200 43 0.8 (0.3 to 2.4) 563 36 1.0 (0.6 to 1.7)
(No moderate or high risk features)
*Derived from multivariate analysis combining participants with intermittent versus sustained AF from this cohort (15).
AF 5 atrial fibrillation.
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studies correlating the frequency and duration of paroxysms
with stroke rates are needed. Selection of antithrombotic
therapy to prevent stroke should be based on the estimated
risk of thromboembolism both for patients with intermit-
tent and sustained AF. Patients with intermittent AF and
additional stroke risk factors have high rates of stroke and
likely benefit from anticoagulation for stroke prevention.
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